1
|
Clark G, Raniwala H, Koppa M, Chen K, Leenheer A, Zimmermann M, Dong M, Li L, Wen YH, Dominguez D, Trusheim M, Gilbert G, Eichenfield M, Englund D. Nanoelectromechanical Control of Spin-Photon Interfaces in a Hybrid Quantum System on Chip. Nano Lett 2024; 24:1316-1323. [PMID: 38227973 PMCID: PMC10835722 DOI: 10.1021/acs.nanolett.3c04301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 01/03/2024] [Accepted: 01/05/2024] [Indexed: 01/18/2024]
Abstract
Color centers (CCs) in nanostructured diamond are promising for optically linked quantum technologies. Scaling to useful applications motivates architectures meeting the following criteria: C1 individual optical addressing of spin qubits; C2 frequency tuning of spin-dependent optical transitions; C3 coherent spin control; C4 active photon routing; C5 scalable manufacturability; and C6 low on-chip power dissipation for cryogenic operations. Here, we introduce an architecture that simultaneously achieves C1-C6. We realize piezoelectric strain control of diamond waveguide-coupled tin vacancy centers with ultralow power dissipation necessary. The DC response of our device allows emitter transition tuning by over 20 GHz, combined with low-power AC control. We show acoustic spin resonance of integrated tin vacancy spins and estimate single-phonon coupling rates over 1 kHz in the resolved sideband regime. Combined with high-speed optical routing, our work opens a path to scalable single-qubit control with optically mediated entangling gates.
Collapse
Affiliation(s)
- Genevieve Clark
- The
MITRE Corporation, 202 Burlington Road, Bedford, Massachusetts 01730, United States
- Research
Laboratory of Electronics, Massachusetts
Institute of Technology, 50 Vassar Street, Cambridge, Massachusetts 02139, United States
| | - Hamza Raniwala
- Research
Laboratory of Electronics, Massachusetts
Institute of Technology, 50 Vassar Street, Cambridge, Massachusetts 02139, United States
| | - Matthew Koppa
- Sandia
National Laboratories, P.O. Box 5800, Albuquerque, New Mexico 87185, United States
| | - Kevin Chen
- Research
Laboratory of Electronics, Massachusetts
Institute of Technology, 50 Vassar Street, Cambridge, Massachusetts 02139, United States
| | - Andrew Leenheer
- Sandia
National Laboratories, P.O. Box 5800, Albuquerque, New Mexico 87185, United States
| | - Matthew Zimmermann
- The
MITRE Corporation, 202 Burlington Road, Bedford, Massachusetts 01730, United States
| | - Mark Dong
- The
MITRE Corporation, 202 Burlington Road, Bedford, Massachusetts 01730, United States
- Research
Laboratory of Electronics, Massachusetts
Institute of Technology, 50 Vassar Street, Cambridge, Massachusetts 02139, United States
| | - Linsen Li
- Research
Laboratory of Electronics, Massachusetts
Institute of Technology, 50 Vassar Street, Cambridge, Massachusetts 02139, United States
| | - Y. Henry Wen
- The
MITRE Corporation, 202 Burlington Road, Bedford, Massachusetts 01730, United States
| | - Daniel Dominguez
- Sandia
National Laboratories, P.O. Box 5800, Albuquerque, New Mexico 87185, United States
| | - Matthew Trusheim
- Research
Laboratory of Electronics, Massachusetts
Institute of Technology, 50 Vassar Street, Cambridge, Massachusetts 02139, United States
- DEVCOM,
Army Research Laboratory, Adelphi, Maryland 20783, United States
| | - Gerald Gilbert
- The
MITRE Corporation, 200
Forrestal Road, Princeton, New Jersey 08540, United States
| | - Matt Eichenfield
- College of
Optical Sciences, University of Arizona, Tucson, Arizona 85719, United States
| | - Dirk Englund
- Research
Laboratory of Electronics, Massachusetts
Institute of Technology, 50 Vassar Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
2
|
Naber SK, Knudsen AB, Zauber AG, Rutter CM, Fischer SE, Pabiniak CJ, Soto B, Kuntz KM, Lansdorp-Vogelaar I. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLoS One 2019; 14:e0220234. [PMID: 31483796 PMCID: PMC6726189 DOI: 10.1371/journal.pone.0220234] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 07/11/2019] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND In 2014, the Centers for Medicare and Medicaid Services (CMS) began covering a multitarget stool DNA (mtSDNA) test for colorectal cancer (CRC) screening of Medicare beneficiaries. In this study, we evaluated whether mtSDNA testing is a cost-effective alternative to other CRC screening strategies reimbursed by CMS, and if not, under what conditions it could be. METHODS We use three independently-developed microsimulation models to simulate a cohort of previously unscreened US 65-year-olds who are screened with triennial mtSDNA testing, or one of six other reimbursed screening strategies. Main outcome measures are discounted life-years gained (LYG) and lifetime costs (CMS perspective), threshold reimbursement rates, and threshold adherence rates. Outcomes are expressed as the median and range across models. RESULTS Compared to no screening, triennial mtSDNA screening resulted in 82 (range: 79-88) LYG per 1,000 simulated individuals. This was more than for five-yearly sigmoidoscopy (80 (range: 71-89) LYG), but fewer than for every other simulated strategy. At its 2017 reimbursement rate of $512, mtSDNA was the most costly strategy, and even if adherence were 30% higher than with other strategies, it would not be a cost-effective alternative. At a substantially reduced reimbursement rate ($6-18), two models found that triennial mtSDNA testing was an efficient and potentially cost-effective screening option. CONCLUSIONS Compared to no screening, triennial mtSDNA screening reduces CRC incidence and mortality at acceptable costs. However, compared to nearly all other CRC screening strategies reimbursed by CMS it is less effective and considerably more costly, making it an inefficient screening option.
Collapse
Affiliation(s)
- Steffie K. Naber
- Erasmus MC, University Medical Center Rotterdam, Department of Public Health, Rotterdam, The Netherlands
| | - Amy B. Knudsen
- Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America
| | - Ann G. Zauber
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
| | - Carolyn M. Rutter
- RAND Corporation, Santa Monica, California, United States of America
| | - Sara E. Fischer
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
| | - Chester J. Pabiniak
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States of America
| | - Brittany Soto
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
| | - Karen M. Kuntz
- Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Iris Lansdorp-Vogelaar
- Erasmus MC, University Medical Center Rotterdam, Department of Public Health, Rotterdam, The Netherlands
| |
Collapse
|